Clinical-stage medical device startup CereVasc, located in Boston, Massachusetts, has secured $70 million in Series B investment.
Investors
- Perceptive Xontogeny Venture Fund (PXV)
- Bain Capital Life Sciences
- an existing investor
Evan Greif, a vice president at Bain Capital Life Sciences, will join CereVasc’s board of directors in conjunction with the funding.
Use of funds
The money will go toward the company’s planned STRIDE pivotal research, which will evaluate the eShunt System in patients with Normal Pressure Hydrocephalus, as well as clinical and regulatory development.
About CereVasc
CereVasc is a clinical stage medical device startup led by CEO Dan Levangie that focuses on developing innovative, minimally invasive solutions for individuals suffering from neurological illnesses. With its first product, the eShunt System, it aims to enhance the existing standard of care by offering the first minimally invasive therapy for communicating hydrocephalus (CH) with percutaneous transvenous-transdural access to the central nervous system.
“Their commitment is a testament to the clinical progress we have made with the eShunt System, and to the potential we have to transform hydrocephalus treatment. We are currently in a good position to carry out our important clinical investigation before receiving regulatory authorization.”
Dan Levangie
